Hormone replacement therapy in gynecologic cancer survivors: Why not?

Okechukwu Ibeanu, Susan C. Modesitt, Jennifer Ducie, Vivian Von Gruenigen, Modupe Agueh, Amanda Nickles Fader

Research output: Research - peer-reviewArticle

Abstract

Purpose: As a result of treatment, many women with gynecologic malignancies will go through menopause and display climacteric symptoms at an earlier age than occurs naturally. Iatrogenic menopause may adversely affect quality of life and health outcomes in young female cancer survivors. Hormone replacement therapy (HRT) has often been withheld from women with gynecologic cancer because of concern that it might increase the risk of relapse or the development of new primary cancers. The purpose of this review was to examine the published literature on menopause management in gynecologic cancer survivors and highlight the risks and benefits of conventional and alternative HRT in this population. Methods: A comprehensive literature search of English language studies on menopause management in gynecologic cancer survivors and women with a hereditary predisposition to a gynecologic malignancy was performed in MEDLINE databases through December 2010. Results: Both our review and a 2008 Cochrane review of randomized trials on the effects of long-term HRT demonstrate that for menopausal women in their 40s or 50s with and without gynecologic cancer, the absolute risks of estrogen-only HRT are low. Several prospective observational studies and randomized trials on HRT use in women with a genetic predisposition for or development of a gynecologic malignancy suggest benefits in quality of life with no proven adverse oncologic effects as a result of short-term HRT use. Conclusion: In select women, it is reasonable to discuss and offer conventional HRT for the amelioration of menopausal symptoms and to improve quality of life. HRT does not appear to increase the risk of gynecologic cancer recurrences; however, this conclusion was largely based on observational data and smaller prospective studies.

LanguageEnglish (US)
Pages447-454
Number of pages8
JournalGynecologic Oncology
Volume122
Issue number2
DOIs
StatePublished - Aug 2011

Fingerprint

Hormone Replacement Therapy
Survivors
Neoplasms
Menopause
Quality of Life
Prospective Studies
Recurrence
Genetic Predisposition to Disease
Complementary Therapies
MEDLINE
Observational Studies
Estrogens
Language
Databases
Health
Population
Therapeutics

Keywords

  • Gynecologic cancer survivor
  • Hormone replacement therapy
  • Menopause
  • Quality of life

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Hormone replacement therapy in gynecologic cancer survivors : Why not? / Ibeanu, Okechukwu; Modesitt, Susan C.; Ducie, Jennifer; Von Gruenigen, Vivian; Agueh, Modupe; Fader, Amanda Nickles.

In: Gynecologic Oncology, Vol. 122, No. 2, 08.2011, p. 447-454.

Research output: Research - peer-reviewArticle

Ibeanu, O, Modesitt, SC, Ducie, J, Von Gruenigen, V, Agueh, M & Fader, AN 2011, 'Hormone replacement therapy in gynecologic cancer survivors: Why not?' Gynecologic Oncology, vol 122, no. 2, pp. 447-454. DOI: 10.1016/j.ygyno.2011.03.012
Ibeanu O, Modesitt SC, Ducie J, Von Gruenigen V, Agueh M, Fader AN. Hormone replacement therapy in gynecologic cancer survivors: Why not? Gynecologic Oncology. 2011 Aug;122(2):447-454. Available from, DOI: 10.1016/j.ygyno.2011.03.012
Ibeanu, Okechukwu ; Modesitt, Susan C. ; Ducie, Jennifer ; Von Gruenigen, Vivian ; Agueh, Modupe ; Fader, Amanda Nickles. / Hormone replacement therapy in gynecologic cancer survivors : Why not?. In: Gynecologic Oncology. 2011 ; Vol. 122, No. 2. pp. 447-454
@article{4e0c76f0f4784cbc80cb4da26f3b52ff,
title = "Hormone replacement therapy in gynecologic cancer survivors: Why not?",
abstract = "Purpose: As a result of treatment, many women with gynecologic malignancies will go through menopause and display climacteric symptoms at an earlier age than occurs naturally. Iatrogenic menopause may adversely affect quality of life and health outcomes in young female cancer survivors. Hormone replacement therapy (HRT) has often been withheld from women with gynecologic cancer because of concern that it might increase the risk of relapse or the development of new primary cancers. The purpose of this review was to examine the published literature on menopause management in gynecologic cancer survivors and highlight the risks and benefits of conventional and alternative HRT in this population. Methods: A comprehensive literature search of English language studies on menopause management in gynecologic cancer survivors and women with a hereditary predisposition to a gynecologic malignancy was performed in MEDLINE databases through December 2010. Results: Both our review and a 2008 Cochrane review of randomized trials on the effects of long-term HRT demonstrate that for menopausal women in their 40s or 50s with and without gynecologic cancer, the absolute risks of estrogen-only HRT are low. Several prospective observational studies and randomized trials on HRT use in women with a genetic predisposition for or development of a gynecologic malignancy suggest benefits in quality of life with no proven adverse oncologic effects as a result of short-term HRT use. Conclusion: In select women, it is reasonable to discuss and offer conventional HRT for the amelioration of menopausal symptoms and to improve quality of life. HRT does not appear to increase the risk of gynecologic cancer recurrences; however, this conclusion was largely based on observational data and smaller prospective studies.",
keywords = "Gynecologic cancer survivor, Hormone replacement therapy, Menopause, Quality of life",
author = "Okechukwu Ibeanu and Modesitt, {Susan C.} and Jennifer Ducie and {Von Gruenigen}, Vivian and Modupe Agueh and Fader, {Amanda Nickles}",
year = "2011",
month = "8",
doi = "10.1016/j.ygyno.2011.03.012",
volume = "122",
pages = "447--454",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Hormone replacement therapy in gynecologic cancer survivors

T2 - Gynecologic Oncology

AU - Ibeanu,Okechukwu

AU - Modesitt,Susan C.

AU - Ducie,Jennifer

AU - Von Gruenigen,Vivian

AU - Agueh,Modupe

AU - Fader,Amanda Nickles

PY - 2011/8

Y1 - 2011/8

N2 - Purpose: As a result of treatment, many women with gynecologic malignancies will go through menopause and display climacteric symptoms at an earlier age than occurs naturally. Iatrogenic menopause may adversely affect quality of life and health outcomes in young female cancer survivors. Hormone replacement therapy (HRT) has often been withheld from women with gynecologic cancer because of concern that it might increase the risk of relapse or the development of new primary cancers. The purpose of this review was to examine the published literature on menopause management in gynecologic cancer survivors and highlight the risks and benefits of conventional and alternative HRT in this population. Methods: A comprehensive literature search of English language studies on menopause management in gynecologic cancer survivors and women with a hereditary predisposition to a gynecologic malignancy was performed in MEDLINE databases through December 2010. Results: Both our review and a 2008 Cochrane review of randomized trials on the effects of long-term HRT demonstrate that for menopausal women in their 40s or 50s with and without gynecologic cancer, the absolute risks of estrogen-only HRT are low. Several prospective observational studies and randomized trials on HRT use in women with a genetic predisposition for or development of a gynecologic malignancy suggest benefits in quality of life with no proven adverse oncologic effects as a result of short-term HRT use. Conclusion: In select women, it is reasonable to discuss and offer conventional HRT for the amelioration of menopausal symptoms and to improve quality of life. HRT does not appear to increase the risk of gynecologic cancer recurrences; however, this conclusion was largely based on observational data and smaller prospective studies.

AB - Purpose: As a result of treatment, many women with gynecologic malignancies will go through menopause and display climacteric symptoms at an earlier age than occurs naturally. Iatrogenic menopause may adversely affect quality of life and health outcomes in young female cancer survivors. Hormone replacement therapy (HRT) has often been withheld from women with gynecologic cancer because of concern that it might increase the risk of relapse or the development of new primary cancers. The purpose of this review was to examine the published literature on menopause management in gynecologic cancer survivors and highlight the risks and benefits of conventional and alternative HRT in this population. Methods: A comprehensive literature search of English language studies on menopause management in gynecologic cancer survivors and women with a hereditary predisposition to a gynecologic malignancy was performed in MEDLINE databases through December 2010. Results: Both our review and a 2008 Cochrane review of randomized trials on the effects of long-term HRT demonstrate that for menopausal women in their 40s or 50s with and without gynecologic cancer, the absolute risks of estrogen-only HRT are low. Several prospective observational studies and randomized trials on HRT use in women with a genetic predisposition for or development of a gynecologic malignancy suggest benefits in quality of life with no proven adverse oncologic effects as a result of short-term HRT use. Conclusion: In select women, it is reasonable to discuss and offer conventional HRT for the amelioration of menopausal symptoms and to improve quality of life. HRT does not appear to increase the risk of gynecologic cancer recurrences; however, this conclusion was largely based on observational data and smaller prospective studies.

KW - Gynecologic cancer survivor

KW - Hormone replacement therapy

KW - Menopause

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=79960451602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960451602&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2011.03.012

DO - 10.1016/j.ygyno.2011.03.012

M3 - Article

VL - 122

SP - 447

EP - 454

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -